MedTrace Logo

TUDCA as a Therapy for Ulcerative Colitis (UC)

NCT04114292 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2026-03-10

No results posted yet for this study

Summary

This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.

Conditions

Interventions

DRUG

Tauroursoursodeoxycholic acid, brand name Tudcabil

Dosed in capsules containing 250 or 500mg of TUDCA for a total dose of 1.75-2g/day

Sponsors & Collaborators

  • Crohn's and Colitis Foundation

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-17
Primary Completion
2022-06-07
Completion
2022-06-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04114292 on ClinicalTrials.gov